Canntab Therapeutics Limited (CTABF) Research

Canntab Therapeutics Limited is a Canadian phytopharmaceutical firm dedicated to pioneering the research and development of sophisticated, pharmaceutical-grade cannabinoid preparations. The company manufactures various oral cannabis medications, including extended-release cannabinoid pills and pellets, rapidly acting cannabidiol formulations, multi-layered modified-release options, quick-dissolving flash-melt products, and dual-layer cannabinoid tablets. These offerings target a broad spectrum of health issues, such as sleep disturbances, post-traumatic stress disorder, social anxiety, various addictions, arthritis, chronic pain, appetite loss and pain linked to cancer therapies, and as an aid in managing dependency on opioids and other painkillers. Canntab Therapeutics Limited operates from its base in Markham, Canada.

Market snapshot

Symbol
CTABF
Price
$0.00
Day change
0.00%
Market cap
$194.5K
P/E ratio
-0.05x
52-week range
0.0001-0.0073
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Cann Group Limited (CNGGF)
  • Captiva Verde Wellness Corp. (CPIVF)
  • LFTD Partners Inc. (LIFD)
  • Resilient Healthcare Corp (NRPR)
  • Rennova Health, Inc. (RNVA)
  • Rapid Nutrition PLC (RPNRF)
  • Revive Therapeutics Ltd. (RVVTF)
  • StateHouse Holdings Inc. (STHZF)

Open Canntab Therapeutics Limited (CTABF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.